15177-67-0

Basic information

• Product Name: TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER
• Synonyms: TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER;TRANS-4-CARBOMETHOXYCYCLOHEXANE-1-CARBOXYLIC ACID;4(METHOXY CARBONYL) CYCLOHEXANE CARBOXYLIC ACID;TRANS-4-(METHOXYCARBONYL)CYCLOHEXANECARBOXYLIC ACID;(1r,4r)-4-(methoxycarbonyl)cyclohexanecarboxylic acid;Methyl trans-4-carboxycyclohexane-1-carboxylate;trans-4-(Methoxycarbonyl)cyclohexane-1-carboxylic acid;TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL
• CAS NO: 15177-67-0
• Molecular Formula: C₉H₁₄O₄
• Molecular Weight: 186.21
• EINECS: 210-614-2
• Product Categories: API
• Mol File: 15177-67-0.mol

Chemical Properties

• Melting Point: 126.0 to 130.0 °C
• Boiling Point: 303.145 °C at 760 mmHg
• Flash Point: 118.334 °C
• Appearance: /
• Density: 1.191 g/cm³
• Vapor Pressure: 0.000219mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER(15177-67-0)
• EPA Substance Registry System: TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER(15177-67-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 15177-67-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER is used as an organic reagent for the synthesis of various chemical compounds. Its ester functional group allows for further reactions and modifications, making it a versatile building block in organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER is used as a key intermediate in the production of certain drugs. Its unique structure and reactivity enable the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Material Science:
TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER is also utilized in the field of material science, where it can be employed in the development of novel polymers and other advanced materials. Its cyclic structure and ester group provide opportunities for creating materials with specific properties, such as enhanced strength, flexibility, or chemical resistance.
Used in Research and Development:
In research and development, TRANS-1,4-CYCLOHEXANEDICARBOXYLIC ACID MONOMETHYL ESTER serves as a valuable compound for studying the properties and behavior of carboxylic acid esters. It can be used to explore new reaction pathways, investigate the effects of structural modifications, and develop a deeper understanding of the underlying chemistry.

InChI:InChI=1/C9H14O4/c1-13-9(12)7-4-2-6(3-5-7)8(10)11/h6-7H,2-5H2,1H3,(H,10,11)/t6-,7+

Upstream product

• 67-56-1 methanol 
• 619-82-9 trans-hexahydroterephthalic acid 
• 3399-22-2 dimethyl 1,4-cyclohexanedicarboxylate 
• 186581-53-3 diazomethane 
• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 32529-80-9 trans-1-chlorocarbonyl-4-(methoxycarbonyl)-cyclohexane 
• 4630-82-4 methyl cyclohexylcarboxylate 
• 3399-22-2 dimethyl 1,4-cyclohexanedicarboxylate 
• 16200-84-3 trans,trans-4',4-bicyclohexanedicarboxylic acid dimethyl ester 
• 688311-48-0 4-[2-oxo-2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-cyclohexanecarboxylic acid methyl ester 
• 127946-00-3 1,3-dipropyl-8-(trans-4-carboxycyclohexyl)xanthine 
• 127946-03-6 4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexanecarboxylic acid methyl ester 
• 127946-12-7 4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexanecarboxylic acid (2-dimethylamino-ethyl)-methyl-amide 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 32529-80-9 4-methoxycarbonylcyclohexanecarbonyl chloride 
• 110928-44-4 trans-(4-hydroxymethyl)cyclohexane-1-carboxylic acid methyl ester 
• 1224871-31-1 4-{4-[5-(3-tert-butyl-phenylcarbamoyl)-pyridin-2-yl]-piperazine-1-carbonyl}-cyclohexanecarboxylic acid methyl ester 

Relevant articles and documents

Magnetic Field Dependent Reaction Yields from Radical Ion Pairs Linked by a Partially Rigid Aliphatic Chain

The electron donor-acceptor compound pyrene-(CH2)3-cyclohexane-(CH2)3-dimethylaniline, abbreviated as Py3(C6)3DMA, has been investigated.Photoinduced electron transfer leads to the singlet radical ion pair Py-3(C6)3DMA+.An extraordinary large and distinct magnetic field effect is observed in the yield of the locally excited triplet state of the pyrene moiety, the recombination product of the triplet radical ion pair.The half-width of the "J-resonance" maximum in the magnetic field dependent triplet yield curve is just 66 G, corresponding to 7.7*10-7 eV or 6.2*10-3 cm-1.This is due to the influence of the rigid trans-cyclohexane part in the aliphatic chain, which leads to a reduced intramolecular mobility and to a narrow probability distribution of the radical ion pair distance, as predicted by Monte-Carlo computer simulations.The magnetic field dependence of the triplet generation is further transmitted to secondary reactions like triplet-triplet annihilation, thus leading to a magnetic field dependent delayed fluorescence and to a delayed excimer fluorescence.

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Preparation method of trans-1,4-cyclohexane dicarboxylic acid monomethyl ester

The invention discloses a preparation method of trans-1,4-cyclohexanedicarboxylic acid monomethyl ester. The preparation method comprises the following steps of using cis and trans mixed type dimethyl1,4-cyclohexanedicarboxylate with better solvent property in organic solvents as the raw material, performing isomerization reaction under the catalyzing action of an organic alkaline catalyst, and performing high-selectivity monoester hydrolyzing under the action of inorganic alkaline, so as to obtain the trans-1,4-cyclohexanedicarboxylic acid monomethyl ester. Compared with the prior art, the preparation method has the advantages that (1) the used raw material has good dissolvability in the organic solvent, such as methyl alcohol; (2) by adopting the optimized catalyst, the activating energy of the isomerization reaction is reduced, the isomerization time is shortened, the reaction energy consumption is decreased, the cost is reduced, and the optimized catalyst is suitable for industrialized production; (3) the hydrolyzing of diester is effectively reduced, the amount of diacid byproducts is reduced to be 2% or lower, and the product purity is improved; (4) a small amount of unreacted raw material is sent into an organic phase via an extracting procedure, and is separated from the product at high efficiency, so that the purity of the product is further improved.

TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR

To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.

Polymerizable compound, composition, polymer, an optically anisotropic material, an organic EL element and a liquid crystal display element

An object of the invention is to provide polymerizable compounds having excellent optical characteristics and suited as materials for optically anisotropic articles, compositions containing the polymerizable compounds, polymers obtained by polymerizing th

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)

FUSED FURAN COMPOUND

The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and , R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.

Design, Synthesis, and Biological Evaluation of Substituted 2-Cyclohexyl-4-phenyl-1H-imidazoles: Potent and Selective Neuropeptide Y Y5-Receptor Antagonists

Antagonizing the robust stimulation of food intake by neuropeptide Y represents a new potential therapeutic approach for the treatment of obesity. Earlier pharmacological studies have pointed to the Y1 and Y5 receptors as the most likely mediators of the